期刊文献+

可溶性血管内皮生长因子受体1与子痫前期的关系研究进展 被引量:4

Progress in Soluble Vascular Endothelial Growth Factor Receptor-1 and Preeclampsia
下载PDF
导出
摘要 子痫前期是妊娠期特有疾病,以高血压和蛋白尿等为临床特征,影响母亲和新生儿的患病率和死亡率。尽管病因至今不明,但多数学者认为其发病与胎盘因子进入母体的血循环引起血管内皮的损伤有关。近年来发现,抗血管生成因子如内皮因子、可溶性血管内皮生长因子受体1(sFlt-1)以及胎盘生长因子都与子痫前期的发生有关。对sFlt-1分子结构及作用、调节因素、相关信号转导途径及其在子痫前期发病机制中的研究结果作一综述。 Pre-eclampsia is a complication of pregnancy characterized by hypertension and proteinuria that results in maternal and neonatal mortality and morbidity.Although the etiology remains unclear,it seems to be initiated by placental factors that enter the maternal circulation and may cause endothelial dysfunction.Recently,anti-angiogenic factors such as endoglin,the soluble form of vascular endothelial growth factor receptor(sFlt-1) as well as the placental growth factor have been found to be associated with the onset of pre-eclampsia.This review will summarize our current understanding of molecular structure of sFlt-1,signal pathways,with an emphasis on its role in the pathogenesis of preeclampsia and regulative factors.
出处 《国际妇产科学杂志》 CAS 2012年第6期560-563,共4页 Journal of International Obstetrics and Gynecology
基金 国家自然科学基金(81070535) 浙江省教育厅科研项目(Y200909349)
关键词 先兆子痫 血管内皮生长因子类 受体 血管内皮生长因子 TOLL样受体3 Pre-eclampsia Vascular endothelial growth factors Receptors vascular endothelial growth factor Tolllike receptor 3
  • 相关文献

参考文献27

  • 1Steegers EA , von Dadelszen P, DuvekotJ J ,et al. Pre-eclampsia[J]. Lancet ,2010 ,376(974l) : 631-644.
  • 2Jacobs M, Nassar N, Roberts CL, et al. Levels of soluble fms -like tyrosine kinase one in first trimester and outcomes of pregnancy: a systematic review[J]. Reprod Bioi Endocrinol,2011,9:77.
  • 3Gastrich MD, Faro R, Rosen T. Markers of preeclampsia and the relationship to cardiovascular disease: review of the twenty -first century literature[J].J Matern Fetal Neonatal Med,2010,23(8): 751-769.
  • 4Boyaud F,Inguimhert N. Soluble fms-like tyrosine kinase-1 anti?body for diagnosis purposes (W02010075475)[J]. Expert Opin Ther Pat ,2011 ,21(6) :971-975.
  • 5Carmeliet P. Angiogenesis in health and disease[J]. Nat Med, 2003,9(6) :653-660.
  • 6夏宝妹,周怀君.血管内皮生长因子家族与抗肿瘤血管生成[J].国际妇产科学杂志,2009,36(2):105-108. 被引量:6
  • 7Wu FT, 5tefanini MO, Mac Gabhann F, et al. A systems biology perspective on s VEGFR 1 : its biological function, pathogenic role and therapeutic use[J].J Cell Mol Med ,2010,14(3) :528-552.
  • 8Yang F .Jin C .Jiang YJ ,et al. Potential role of soluble VEGFR-1 in antiangiogenesis therapy for cancer[J]. Expert Rev Anticancer Ther ,2011, II (4) :541-549.
  • 9Shibuya M. Involvement of FIt-1 (VEGF receptor-L) in cancer and preeclampsia[J]. ProcJpn Acad Ser B Phys Bioi 5ci,2011,87(4): 167-178.
  • 10De Vivo A, Baviera G, Giordano D, et al. Endoglin, PIGF and sFlt-1 as markers for predicting pre-eclampsia[J]. Acta Dhstet Gynecol Scand,2oo8,87(8):837-842.

二级参考文献20

  • 1Ozalp S,Yalein OT,Acikalin M,et al.Microvessel density(MVD) as a prognosticator in endometrial carcinoma[J].Eur J Gynaccol Onc01.2003,24(3/4):305-308.
  • 2Akutagawa N,Nishikawa A,Iwasaki M,et al.Expression of vascular endothelial growth factor and E-cadherin in human ovarian cancer:association with ascites fluid accumulation and peritoneal dissemination in mouse ascites model[J].Jpn J Cancer Res,2002,93(6):644-651.
  • 3Kamiyama M,lchikawa Y,lshikawa T,et al.VEGF receptor antisense therapy inhibits angiogenesis and peritoneal dissemination of human gastric cancer in nude mice[J].Cancer GeneTherr 2002,9(2):197-201.
  • 4ciafrè SA.Niola F,Wannenes F,et al.An anti-VEGF ribozyme embedded within the adenoviral VAI sequence inhibits glioblastoma cell angiogenic potential in vitro[J].J Vasc Res,2004,41(3):220-228.
  • 5Takei Y,Kadomatsu K,Yuzawa Y,et al.A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics[J].Cancer Res,2004,64(10):3365-3370.
  • 6K0ldehoff M,Beelen DW,Elmaagacli AH.Small-molecule inhibition of proteasome and silencing by vascular endothelial cell growth factor-specific siRNA induce additive antitumor activity in muhiple myeloma[J].J Leukoc Biol,2008,84(2):561-576.
  • 7Kim ES,Seror A,Huang J,et al.Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma[J].Proc Natl Acad Sci U S A,2002,99(17):11399-11404.
  • 8Miller KD,Chap LI,Holmes FA,et al.Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in Dalients with previously treated metastatic breast cancer[J].J Clin Onc01.2005,23(4):792-799.
  • 9Nimeiri HS,Oza AM,Morgan RJ,et al.Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian,primary petitoneal,and fallopian tube cancer:a trial of the Chicago,PMH.and California Phase II Consortia[J].Gynecol Oncol,2008,110(1):49-55.
  • 10Lindsey H.Bevacizumab and erlotinib show promise tor kidney cancer[J].Lancet Oncol,2006,7(1):15.

共引文献5

同被引文献61

引证文献4

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部